1. Home
  2. Live Updates
  3. Pediatric infectious disease

Live Breaking News & Updates on Pediatric infectious disease

Stay informed with the latest breaking news from Pediatric infectious disease on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pediatric infectious disease and stay connected to the pulse of your community

European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease

NEW YORK, March 13, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.

Espa , Hordaland , Norway , Brazil , Australia , Canada , Liechtenstein , Spain , United-states , Iceland , Italy , Lichtenstein

European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease -March 13, 2024 at 04:03 am EDT

PREVENAR 20® offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of...

Espa , Hordaland , Norway , Spain , Liechtenstein , Brazil , Canada , Australia , Italy , United-states , Iceland , Lichtenstein

European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease | Nation/World

NEW YORK--(BUSINESS WIRE)--Mar 13, 2024--

Espa , Hordaland , Norway , Brazil , Australia , Liechtenstein , Spain , Iceland , Italy , United-states , Canada , Lichtenstein

European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease | Region

NEW YORK--(BUSINESS WIRE)--Mar 13, 2024--

Espa , Hordaland , Norway , United-states , Brazil , Liechtenstein , Iceland , Canada , Australia , Italy , Spain , Lichtenstein

Fighting the trifecta of flu, COVID-19 and RSV viruses as Utah cases rise

If you know or are someone who has been fighting off a case of the flu, COVID-19, or RSV in the early weeks of 2024, you are not alone.

Utah , United-states , University-of-utah , Andrew-pavia , University-of-utah-health , Young , Centers-for-disease , Pediatric-infectious-disease , Primary-children , Disease-control , News , Raffic

Less than 5% of US preschool cohort hospitalized for COVID were fully vaccinated, study finds

Less than 5% of US preschool cohort hospitalized for COVID were fully vaccinated, study finds
umn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umn.edu Daily Mail and Mail on Sunday newspapers.

Pfizer , Centers-for-disease , Pediatric-infectious-disease , Disease-control ,

FDA approves expanded use of Astella's Cresemba

Cresemba is the only azole antifungal therapy approved for pediatric patients affected by these serious, potentially life-threatening infections.

Antonio-arrieta , Astellas-pharma , Drug-administration , Children-health-of-orange , Pediatric-infectious-disease ,

What Is Enterovirus D68?

What Is Enterovirus D68?
theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.

Missouri , United-states , Saul-hymes , Department-of-pediatrics , Assistant-professor , Stony-brook-children , Pediatric-infectious-disease , Kansas-city , East-coast ,

FDA Approves Isavuconazonium Sulfate to Treat Invasive Aspergillosis and Invasive Mucormycotic

The approval marks isavuconazonium sulfate as the only granted azole antifungal therapy for pediatric individuals AI and IM that are as young as 1 years old.

Lynn-fenicchia , Antonioc-arrieta , Astellas-pharma-us-inc , Children-health-of-orange , Astellas-pharma , Pediatric-infectious-disease , Orange-county , Specialties-business-unit ,

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

/PRNewswire/ -- Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved...

United-states , Syria , Aram , Stevens-johnson , Antonioc-arrieta , Mark-reisenauer , Lynn-fenicchia , Drug-administration , Prnewswire-astellas-pharma-us-inc , Facebook , Basilea-pharmaceutica-international-ltd , Astellas-pharma-us-inc